SV

Street Verdict

Analyst Scorecard

A record of what Goldman Sachs Analysis said publicly, with the source. Not advice.

“Bullish on Piramal Pharmaceuticals with a target price of ₹250 per share. Despite transitory near-term pressure in CDMO in FY26 due to destocking, the company is well-placed for top-quartile profit growth driven by high operating/financial leverage as the CDMO business recovers post-FY26, CHG capacity ramps up from 2HFY26, and the ICH business turns around.”

Goldman Sachs Analysis’s track record (trackable calls only): 63 graded calls · 95% CI 39–63%

Piramal Pharma LtdBullishCalled 12 Nov 2025Graded 12 Nov 2026
Verdict:MISS

R4 TARGET_CALL: entered ₹193.84 on 2025-11-13 (next trading session's close); neither target nor stop reached by window end 2026-11-12. Window 365 days — rule H3: a target call whose quote states no time frame is given 12 months, the broker convention.

How it played out

How this is worked out
Time to target
The target was not reached on a close inside the window.
Worst close against it
The closing price went as far as 31.25% against the call up to 12 Nov 2026, when the call was decided, measured from the entry price. Closing prices only; an intraday dip is never counted.

From the entry the grade used, on closing prices. This is a record of one past call and is not advice.

Read the original articleSee Goldman Sachs Analysis’s full track record